Bakay, U. and İzci Duran, T. 2025. Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. Archives of Rheumatology. 40, 4 (Dec. 2025), 465–473. DOI:https://doi.org/10.5152/ArchRheumatol.2025.11098.